Diabetic retinopathy and diabetic macular edema: Pathophysiology, screening, and novel therapies

Diabetes Care

Volumn 26, Issue 9, 2003, Pages 2653-2664

  Ciulla, Thomas A ^a   Amador, Armando G ^b   Zinman, Bernard ^c,d  

^a MIDWEST EYE INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d Leadership Sinai Centre for Diabetes   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; CARBOHYDRATE; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FLUORESCEIN; FRUCTOSE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL; PONALRESTAT; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; SORBINIL; SORBITOL; TOCOPHEROL; TOLRESTAT; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

BIOACCUMULATION; BLINDNESS; BLOOD VESSEL INJURY; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME ACTIVATION; FLUORESCENCE ANGIOGRAPHY; FUNCTIONAL DISEASE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; LASER COAGULATION; MASS SCREENING; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PROTEIN SYNTHESIS; RETINA MACULA EDEMA; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TECHNIQUE; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY;

EID: 0041358796     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.9.2653     Document Type: Review

References (146)

1. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS: Diabetes trends in the U.S.: 1990-1998. Diabetes Care 23:1278-1283, 2000
2. MacKinnon JR, Forrester JV: Diabetetic retinopathy. In Oxford Textbook of Endocrinology and Diabetes. Wass JAH, Shalet SM, Eds. Oxford, U.K., Oxford University Press, 2002, p. 1764-1778
3. Centers for Disease Control and Prevention: Blindness caused by diabetes: Massachusetts, 1987-1994. MMWR 45:937-941, 1996
4. Moss SE, Klein R, Klein BE: The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105:998-1003, 1998
5. Riordan-Eva P: Eye. In Current Medical Diagnosis and Treatment. 42nd ed. Tierney LM, McPhee SJ, Papadakis MA, Eds. New York, Lange Medical Books/McGraw-Hill, 2003, p. 146-177
6. Klein R, Klein BEK, Moss SE, Cruickshanks K: The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XV: the long-term incidence of macular edema. Ophthalmology 102:7-16, 1995
7. Ferris FL III, Patz A: Macular edema: a complication of diabetic retinopathy. Surv Ophthalmol 28 (Suppl.):452-461, 1984
8. Rahmani B, Tielsch JM, Katz J, Gottsch J, Quigley H, Javitt J, Sommer A: The cause-specific prevalence of visual impairment in an urban population: the Baltimore Eye Survey. Ophthalmology 103:1721-1726, 1996
9. Chiang YP, Bassi LJ, Javitt JC: Federal budgetary costs of blindness. Milbank Q 70:319-340, 1992
10. Brown MM, Brown GC, Sharma S, Shah G: Utility values and diabetic retinopathy. Am J Ophthalmol 128:324-330, 1999
11. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260:2864-2871, 1988
12. Vitale S, Maguire MG, Murphy RP, Hiner CJ, Rourke L, Sackett C, Patz A: Clinically significant macular edema in type I diabetes. Ophthalmology 102:1170-1176, 1995
13. Chew EY, Klein ML, Ferris FL III, Remaley NA, Murphy RP, Chantry K, Hoogwerf BJ, Miller D: ETDRS Researc Group: association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment of Diabetic Retinopathy Study (ETDRS) Report No 22. Arch Ophthalmol 114:1079-1084, 1996
14. Klein R, Klein BEK, Moss SE, Cruickshanks K: The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type I diabetes. Ophthalmology 105:1801-1815, 1998
15. Kubawara T, Cogan DG: Retinal vascular patterns, VI: mural cells of the retinal capillaries. Arch Ophthalmol 69:492-502, 1962
16. Sims DE: The pericyte: a review. Tissue Cell 18:153-174, 1986
17. Antonelli-Orlidge A, Smith SR, D'Amore PA: Influence of pericytes on capillary endothelial cell growth. Am Rev Respir Dis 140:1129-1131, 1989
18. Antcliff RJ, Marshall J: The pathogenes of edema in diabetic maculopathy. Semin Ophthalmol 14:223-232, 1999
19. Ciulla TA, Harris A, Latkany P, Piper HC, Arend O, Garzozi H, Martin B: Ocular perfusion abnormalities in diabetes. Acta Ophthalmol Scand 80:468-477, 2002
20. Speiser P, Gittelsohn AM, Patz A: Studies on diabetic retinopathy, III: influence diabetes on intramural pericytes. Arch Ophthalmol 80:332-337, 1968
21. Ansari NH, Zhang W, Fulep E, Mansour A: Prevention of pericyte loss by trolox in diabetic rat retina. J Toxicol Environ Health A 54:467-475, 1998
22. Paget C, Lecomte M, Ruggiero D, Wiernperger N, Lagarde M: Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products. Free Radic Biol Med 25:121-129, 1998
23. Cogan DG, Toussaint D, Kubawara T: Retinal vascular patterns, IV: diabetic retinopathy. Arch Ophthalmol 66:366-378, 1961
24. Mogensen CE, Osterby R, Gundersen HJ: Early functional and morphologic vascular renal consequences of the diabetic state. Diabetologia 17:71-76, 1979
25. Williamson JR, Kilo C: Extracellular matrix changes in diabetes mellitus. In Comparative Pathobiology of Major Age-Related Diseases. Scarpelli DG, Migal DG, Eds. New York, Liss, 1984, p. 269-288
26. Koya D, King GL: Protein kinase C activation and the development of diabetic complications. Diabetes 47:859-866, 1998
27. Miyamoto K, Ogura Y: Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol 14:233-239, 1999
28. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP: Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 96:10836-10841, 1999
29. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487, 1994
30. Miller JW, Adamis AP, Aiello LP: Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 13:37-50, 1997
31. Hutchinson A, McIntosh A, Peters J, O'Keeffe C, Khunti K, Baker R, Booth A: Effectiveness of screening and monitoring tests for diabetic retinopathy: a systematic review. Diabet Med 17:495-506, 2000
32. American Diabetes Association: Diabetic retinopathy. Diabetes Care 23 (Suppl. 1): S73-S76, 2000
33. Singer DE, Nathan DM, Fogel HA, Schachat AP: Screening for diabetic retinopathy. Ann Intern Med 116:660-671, 1992
34. Early Treatment Diabetic Retinopathy Study Research Group: Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification: ETDRS Report No 10. Ophthalmology 98(Suppl.):786-806, 1991
35. American Academy of Ophthalmology: Diabetic Retinopathy Disease Severity Scale. 2002. Available from http://www.aao.org/aao/education/library/international_DR.cfm. Accessed 14 January 2003
36. Klein R, Klein BE, Moss SE: How many steps of progression ofo[ diabetic retinopathy are meaningful? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol 119:547-553, 2001
37. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report No. 1. Arch Ophthalmol 103:1796-1806, 1985
38. Ferris FL III: How effective are treatments for diabetic retinopathy? JAMA 269:1290-1291, 1993
39. Bailey CC, Sparrow JM, Grey RH, Cheng H: The National Diabetic Retinopathy Laser Treatment Audit, III: clinical outcomes. Eye 13:151-159, 1999
40. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389, 2000
41. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK: Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 38:437-444, 1995
42. Shiba T, Yamamoto T, Seki U, Utsugi N, Fujita K, Sato Y, Terada H, Sekihara H, Hagura R: Screening and follow-up of diabetic retinopathy using a new mosaic 9-filed fundus photography system. Diabetes Res Clin Pract 55:49-59, 2002
43. Newsom R, Moate B, Casswell T: Screening for diabetic retinopathy using digital colour photography and oral fluorescein angiography. Eye 14:579-582, 2000
44. Bursell SE, Cavallerano JD, Cavallerano AA, Clermont AC, Birkmire-Peters D, Aiello LP, Aiello LM: Stereo nonmydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy. Ophthalmology 108:572-585, 2001
45. Liesenfeld B, Kohner E, Piehlmeier W, Kluthe S, Aldington S, Porta M, Bek T, Obermaier M, Mayer H, Mann G, Holle R, Hepp KD: A telemedical approach to the screening of diabetic retinopathy: digital fundus photography. Diabetes Care 23:345-348, 2000
46. Cook HL, Heacock GL, Stanford MR, Marshall J: Detection of retinal lesions after telemedicine transmission of digital images. Eye 14:563-571, 2000
47. Gómez-Ulla F, Fernandez MI, Gonzalez F, Rey P, Rodriguez M, Rodriguez-Cid MJ, Casanueva FF, Tome MA, Garcia-Tobio J, Gude F: Digital retinal images and teleophthalmology for detecting and grading diabetic retinopathy. Diabetes Care 25:1384-1389, 2002
48. Sinthanayothin C, Boyce JF, Williamson TH, Cook HL, Mensah E, Lal S, Usher D: Automated detection of diabetic retinopathy on digital fundus images, Diabet Med 19:105-112, 2002
49. Moss SE, Klein R, Kessler SD, Richie KA: Comparison between ophthalmoscopy and fundus photography in determining severity of retinopathy. Ophthalmoscopy 92:62-67, 1985
50. Owens DR, Gibbins RL, Lewis PA, Wall S, Allen JC, Morton R: Screening for diabetic retinopathy by general practitioners: ophthalmoscopy or retinal photography as 35 mm colour transparencies? Diabet Med 15:170-175, 1998
51. Griffith SP, Freeman WL, Shaw CJ, Mitchell WH, Olden CR, Figgs LD, Kinyoun JL, Underwood DL, Will JC: Screening for diabetic retinopathy in a clinical setting: a comparison of direct ophthalmoscopy by primary care physicians with fundus photography. J Fam Pract 37:49-56, 1993
52. Harding SP, Broadbent DM, Neoh C, White MC, Vora J: Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool Diabetic Eye Study. Br Med J 311:1131-1135, 1995
53. Kinyoun JL, Martin DC, Fujimoto WY, Leonetti DL: Ophthalmoscopy versus fundus photographs for detecting and grading diabetic retinopathy. Invest Ophthalmol Vis Sci 33:1888-1893, 1992
54. Hara T, Inami M, Hara T: Efficacy and safety of fluorescein angiography with orally administered sodium fluorescein. Am J Ophthalmol 126:560-564, 1998
55. Cunha-Vaz JG: Diabetic retinopathy: surrogate outcomes for drug development for diabetic retinopathy. Ophthalmologica 214:377-380, 2000
56. Cree MJ, Olson JA, McHardy KC, Sharp PF, Forrester JV: A fully automated comparative microaneurysm digital detection system. Eye 11:622-638, 1997
57. Agardh E, Cavallin-Sjoberg U: Peripheral retinal evaluation comparing fundus photographs with fluorescein angiograms in patients with diabetes mellitus. Retina 18:420-423, 1998
58. Diabetes Control and Complications Trial Research Group: Color photography vs fluorescein angiography in the detection of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol 105:1344-1352, 1987
59. Ivanisevic M, Stanic R: Importance of fluorescein angiography in the early detection and therapy of diabetic retinopathy. Ophthalmologica 201:9-13, 1990
60. Pacurariu RI: Low incidence of side effects following intravenous fluorescein angiography. Ann Ophthalmol 14:32-36, 1982
61. Malone JI, Morrison AD, Pavan PR, Cuthbertson DD: Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years' duration screened for the Diabetes Control and Complications Trial. Diabetes Care 24:522-526, 2001
62. Brechner RJ, Cowie CC, Howie LJ, Herman WH, Will JC, Harris MI: Ophthalmic examination among adults with diagnosed diabetes mellitus. JAMA 270:1714-1718, 1993
63. Mukamel DB, Bresnick GH, Wang Q, Dickey CF: Barriers to compliance in screening guidelines for diabetic retinopathy. Ophthalmic Epidemiol 6:61-72, 1999
64. Schoenfeld ER, Greene JM, Wu SY, Leske MC: Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program. Ophthalmology 108:563-571, 2001
65. Klein R, Klein BE: Screening for diabetic retinopathy, revisited. Am J Ophthalmol 134:261-263, 2002
66. Aiello LP, Cahill MT, Wong JS: Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 132:760-776, 2001
67. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
68. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 352:837-853, 1998
69. Chaturvedi N, Sjolie A-K, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH: EUCLID Study Group: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 351:28-31, 1998
70. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 317:713-720, 1998
71. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317:703-713, 1998
72. Klein BEK, Moss SE, Klein R, Surawicz TS: The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XIII: relationship of serum cholesterol to retinopathy hard exudate. Ophthalmology 98:1261-1265, 1991
73. Gordon B, Chang S, Kavanagh M, Berrocal M, Yannuzzi L, Robertson C, Drexler A: The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 112:385-391, 1991
74. American Association of Clinical Endocrinologists: The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management: 2000 update. Endocr Pract 6:43-84, 2000
75. Chase HP, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J, Garg SK: The impact of the Diabetes Control and Complications Trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 24:430-434, 2001
76. The Diabetic Retinopathy Study (DRS) Research Group: Preliminary report on the effects of photocoagulation therapy: DRS Report No. 1. Am J Ophthalmol 81:383-396, 1976
77. Early Treatment Diabetic Retinopathy Study Research Group: Early photocoagulation for diabetic retinopathy: ETDRS Report No 9. Ophthalmology 98 (Suppl.):766-785, 1991
78. Ai E: Current management of diabetic retinopathy. West J Med 157:67-70, 1992
79. Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report No. 2. Ophthalmology 94:761-774, 1987
80. Raskin P, Arauz-Pacheco C: The treatment of diabetic retinopathy: a view for the internist. Ann Intern Med 117:226-233, 1992
81. Ho T, Smiddy WE, Flynn HW Jr: Vitrectomy in the management of diabetic eye disease. Surv Ophthalmol 37:190-202, 1992
82. Arrigg PG, Cavallerano J: The role of vitrectomy for diabetic retinopathy. J Am Optom Assoc 69:733-740, 1998
83. Capone A Jr, Panozzo G: Vitrectomy for refractory diabetic macular edema. Semin Ophthalmol 15:78-80, 2000
84. Diabetic Retinopathy Vitrectomy Study Research Group: Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report No 3. Ophthalmology 95:1307-1320, 1988
85. Diabetic Retinopathy Vitrectomy Study Research Group: Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report No 5. Arch Ophthalmol 108:958-964, 1990
86. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK: The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis. Curr Opin Ophthalmol 11:175-179, 2000
87. Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM: The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol 12:230-234, 2001
88. Lewis H, Abrams GW, Blumenkranz MS, Campo RV: Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 99:753-759, 1992
89. Kowluru RA: Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol 38:179-185, 2001
90. Nishikawa T, Edelstein D, Brownlee M: The missing link: a single unifying mechanism for diabetic complications. Kidney Int 58 (Suppl. 77):S26-S30, 2000
91. Gabbay KH: Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Annu Rev Med 26:521-535, 1975
92. Sato S, Secchi EF, Lizak MJ, Fukase S, Ohta N, Murata M, Tsai JY, Kador PF: Polyol formation and NADPH-dependent reductases in dog retinal capillary pericytes and endothelial cells. Invest Ophthalmol Vis Sci 40:697-704, 1999
93. Del Monte MA, Rabbani R, Diaz TC, Lattimer SA, Nakamura J, Brennan MC, Greene DA: Sorbitol, myo-inositol, and rod outer segment phagocytosis in cultured hRPE cells exposed to glucose: in vitro model of myo-inositol depletion hypothesis of diabetic complications. Diabetes 40:1335-1345, 1991
94. Li WY, Tang L, Zhou Q, Qin M, Hu TS: DNA-synthesis regulation and correlation with inositol trisphosphate levels in cultured bovine retinal capillary pericytes. Exp Eye Res 49:677-683, 1989
95. Li WY, Zhou Q, Qin M, Tao L, Lou M, Hu TS: Reduced absolute rate of myo-inositol biosynthesis of cultured bovine retinal capillary pericytes in high glucose. Exp Eye Res 52:569-573, 1991
96. Sorbinil Retinopathy Trial Research Group: A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 108:1234-1244, 1990
97. Tromp A, Hooymans JM, Barendsen BC, van Doormaal JJ: The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy. Doc Ophthalmol 78:153-159, 1991
98. Arauz-Pacheco C, Ramirez LC, Pruneda L, Sanborn GE, Rosenstock J, Raskin P: The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy. J Diabetes Complications 6:131-137, 1992
99. van Gerven JM, Boot JP, Lemkes HH, van Best JA: Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. Doc Ophthalmol 87:355-365, 1994
100. Engerman RL, Kern TS, Larson ME: Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosemia in dogs. Diabetologia 37:141-144, 1994
101. Brownlee M, Vlassara H, Cerami A: Non-enzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 101:527-537, 1984
102. Friedman EA: Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care 22 (Suppl. 2):B65-B71, 1999
103. Schmidt AM, Yan SD, Wautier J-L, Stern D: Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84:489-497, 1999
104. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: a review. Diabetologia 44:129-146, 2001
105. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Set U S A 88:11555-11558, 1991
106. Kowluru RA, Engerman RL, Kern TS: Abnormalities of retinal metabolism in diabetes or experimental galactosemia, VIII: prevention by aminoguanidine. Curr Eye Res 21:814-819, 2000
107. Kern TS, Engerman RL: Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 50:1636-1642, 2001
108. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS: Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II). Control Clin Trials 20:493-510, 1999
109. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 89:11059-11063, 1992
110. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL: Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 43:1122-1129, 1994
111. Taher MM, Garcia JG, Natarajan V: Hydroperoxide-induced diacylglycerol formation and protein kinase C activation in vascular endothelial cells. Arch Biochem Biophys 303:260-266, 1993
112. Nagpala P, Malik AB, Vuong PT, Lum H: Protein kinase C b1 overexpression augments phorbol ester-induced increase in endothelial permeability. J Cell Physiol 166:249-255, 1996
113. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98:2018-2026, 1996
114. Takahara N, Clermont A, Kagokawa H, Takahara H, Kurihara H, Bursell S, King GL: Transgenic mice overexpressing protein kinase C β isoform mimicked the early changes of diabetes (Abstract). Diabetes 48:A138, 1999
115. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH III, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Baevsky M, Ballas LM, Hall SE, Winneroski LL, Paul MM: (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C β. J Med Chem 39:2664-2671, 1996
116. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 272:728-731, 1996
117. Danis RP, Bingaman DP, Jirousek MR, Yang Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCβ inhibition with LY333531. Invest Ophthalmol Vis Sci 39:171-179, 1998
118. Aiello LP, Bursell S-E, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 46:1473-1480, 1997
119. Aiello LP, Bursell S, Devries T, Alatorre C, King GL, Ways K: Protein kinase C β selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes (Abstract). Diabetes 48:A19, 1999
120. Seo MS, Kwak N, Ozaki H, Yamada H, Okamoto N, Yamada E, Fabbro D, Hofmann F, Wood JM, Campochiaro PA: Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 154:1743-1753, 1999
121. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T: PKC412: a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15:17-28, 2000
122. Propper DJ, McDonald A, Man P, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye SB, Ganesan TS, Talbot DC, Harris AL, Twelves C: Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19:1485-1492, 2001
123. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19:257-267, 1996
124. Bursell SE, Clermont AC, Aiello LP, Aiello LM, Schlossman DK, Feener EP, Laffel L, King GL: High dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type I diabetes. Diabetes Care 22:1245-1251, 1999
125. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790, 2000
126. Brignardello E, Beltramo E, Molinatti PA, Aragno M, Gatto V, Tamagno E, Danni O, Porta M, Boccuzzi G: Dehydro-epiandrosterone protects bovine retinal capillary pericytes against glucose toxicity. J Endocrinol 158:21-26, 1998
127. Kunisaki M, Bursell S-E, Clermont AC, Ishii H, Ballas LM, Jirousek MR, Umeda F, Nawata H, King GL: Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol 269: E239-E246, 1995
128. Bursell S-E, King GL: Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications? Diabetes Res Clin Pract 45:169-182, 1999
129. Gey KF: The antioxidant hypothesis of cardiovascular disease: epidemiology and mechanisms. Biochem Soc Trans 18:1041-1045, 1990
130. Hoogwerf BJ, Young JB: The HOPE study: ramipril lowered cardiovascular risk, but vitamin E did not. Cleveland Clin J Med 67:287-293, 2000
131. Pruthi S, Allison TG, Hensrud DD: Vitamin E supplementation in the prevention of coronary heart disease. Mayo Clin Proc 76:1131-1136, 2001
132. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368:237-239, 1994
133. Penn JS, Rajaratnam VS, Collier RJ, Clark AF: The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 42:283-290, 2001
134. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997
135. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245-248, 1999
136. Stellmach V, Crawford SE, Zhou W, Bouck N: Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 98:2593-2597, 2001
137. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert JP, Vague P. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabetes Metab 8:438-444, 1992
138. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, Estes KS: The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative dia-betic retinopathy. Diabetes Care 23:504-509, 2000
139. McCombe M, Lightman S, Eckland DJ, Hamilton AM, Lightman SL: Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study. Eye 5:569-575, 1991
140. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adamis AP: Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16:438-440, 2002
141. The DAMAD Study Group: Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter randomized controlled clinical trial. Diabetes 38:491-498, 1989
142. Early Treatment Diabetic Retinopathy Study Research Group: Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8. Ophthalmology 98 (Suppl.):757-765, 1991
143. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 317:713-772, 1998
144. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S, Skinner SL, Wilkinson-Berka JL: Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 36:1099-1104, 2000
145. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T, Panagiotopoulos S, Lee V, Hendrich EC, Jerums G, Cooper ME: Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 43:1360-1367, 2000
146. Nagisa Y, Shintani A, Nakagawa S: The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia 44:883-888, 2001